|
CEP70 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.93522975422411E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.41409994824926E-10 |
| Normal-vs-Stage2 |
2.247800E-04 |
| Normal-vs-Stage3 |
6.66133814775094E-15 |
| Normal-vs-Stage4 |
1.63280500231622E-12 |
| Stage1-vs-Stage2 |
2.367200E-01 |
| Stage1-vs-Stage3 |
6.137100E-03 |
| Stage1-vs-Stage4 |
4.367200E-04 |
| Stage2-vs-Stage3 |
3.955200E-03 |
| Stage2-vs-Stage4 |
1.236980E-03 |
| Stage3-vs-Stage4 |
3.051400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.33066907387547E-16 |
| Normal-vs-AfricanAmerican |
5.503100E-03 |
| Normal-vs-Asian |
7.54859996732193E-09 |
| Caucasian-vs-AfricanAmerican |
5.526000E-02 |
| Caucasian-vs-Asian |
2.977600E-01 |
| AfricanAmerican-vs-Asian |
3.901600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.84106072001578E-13 |
| Normal-vs-Female |
1.25319754573638E-11 |
| Male-vs-Female |
1.557600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.36570002371184E-10 |
| Normal-vs-Age(41-60Yrs) |
3.39062111720523E-13 |
| Normal-vs-Age(61-80Yrs) |
3.55870000134928E-09 |
| Normal-vs-Age(81-100Yrs) |
2.232900E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.052400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.813600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.629000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.246000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.525400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.951400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.446460E-04 |
| Classical-VS-Follicular |
7.99830000000057E-05 |
| Classical-VS-Other |
4.183800E-01 |
| Classical-VS-Normal |
1.62536650805123E-12 |
| Tall-VS-Follicular |
3.02000002783132E-09 |
| Tall-VS-Other |
3.816800E-01 |
| Tall-VS-Normal |
1.62458935193399E-12 |
| Follicular-VS-Other |
6.472300E-02 |
| Follicular-VS-Normal |
2.456100E-03 |
| Other-VS-Normal |
5.77309999999498E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.85260037813373E-10 |
| Normal-vs-N1 |
5.88418203051333E-15 |
| N0-vs-N1 |
4.200000E-04 |
|
|
